UBS Maintains a 'Neutral' on Bristol-Myers Squibb Co. (BMY); Brivanib Misses in HCC
Tweet Send to a Friend
UBS maintains a 'Neutral' on Bristol-Myers Squibb Co. (NYSE: BMY) price target of $36.00
Analyst, Marc Goodman, takes note ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Analyst, Marc Goodman, takes note ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
